T. Tsuchitani

发表

Accessibility Measurement by the Cumulative-Opportunity Method

T. Tsuchitani, 1986 .

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion

T. Shiraishi, Y. Nio, M. Fukumoto, 1999, British Journal of Cancer.

[Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].

Y. Nio, T. Tobe, H. Kodama, 1985, Nihon Gan Chiryo Gakkai shi.

Synergy is documented in vitro with low‐dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells

B. Bonavida, J. Berek, J. Zighelboim, 1991, Gynecologic oncology.

Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.

J. Berek, B. Bonavida, J. Zighelboim, 1990 .

[A new anti-cancer agent K-18 (conjugate of human IgG and melphalan). (II). Its inhibitory effects on in vitro DNA synthesis of human tumor cells].

Y. Nio, T. Tobe, N. Kan, 1986, Nihon Gan Chiryo Gakkai shi.

[A new anti-cancer agent K-18 (conjugate of human IgG and melphalan). (I). K-18 accumulates selectively into the tumor].

Y. Nio, T. Tobe, K. Ohgaki, 1986, Nihon Gan Chiryo Gakkai shi.

Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer

T. Shiraishi, Y. Nio, T. Tobe, 1990, Biotherapy.